Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue
- PMID: 34091823
- DOI: 10.1007/s10753-021-01493-0
Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue
Abstract
Gasdermins (GSDM) are members of a family of pore-forming effector proteins which lead to membrane permeabilization and pyroptosis, a lytic cell death with pro-inflammatory characteristics. Recently, two members of the gasdermin family, gasdermin B (GSDMB) and gasdermin E (GSDME), were shown to suppress tumor growth, through the involvement of cytotoxic lymphocytes. Other studies also reported the important functions of gasdermins in various cancer types including gastric cancer, hepatocarcinoma, and cervix and breast cancer. However, gasdermins have not been previously studied in the context of serous ovarian cancer. Here, we showed that gasdermin D (GSDMD) and gasdermin C (GSDMC) expression increases in serous ovarian cancer; in contrast, the expression of GSDME and PJVK (Pejvakin, DFNB59) is downregulated, compared to healthy ovaries, in multiple independent gene expression datasets. We found that copy number gains are highly frequent (present in approximately 50% of patients) in genes encoding GSDMD and GSDMC in ovarian cancer, in line with their upregulated expression in serous ovarian cancer. Moreover, we observed that the expression of GSDMB and GSDMD, but not of GSDME, is different among several histotypes of epithelial ovarian cancer. Therefore, we propose that differential expression and copy number variations of certain gasdermins might be associated with the development of serous ovarian cancer, in which different members of the family have distinct functions; however, further research is required in in vivo models to understand how changes in gasdermin family members mechanistically contribute to serous ovarian cancer.
Keywords: epithelial ovarian cancer; gasdermin; gasdermin D (GSDMD); gasdermin E (GSDME); inflammation; pyroptosis; serous ovarian cancer, tumor initiation.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Pyroptosis, inflammasome, and gasdermins in tumor immunity.Innate Immun. 2023 Jan;29(1-2):3-13. doi: 10.1177/17534259221143216. Epub 2023 Jan 11. Innate Immun. 2023. PMID: 36632024 Free PMC article. Review.
-
Monitoring gasdermin pore formation in vitro.Methods Enzymol. 2019;625:95-107. doi: 10.1016/bs.mie.2019.04.024. Epub 2019 May 23. Methods Enzymol. 2019. PMID: 31455540 Free PMC article.
-
Structural Insight of Gasdermin Family Driving Pyroptotic Cell Death.Adv Exp Med Biol. 2019;1172:189-205. doi: 10.1007/978-981-13-9367-9_9. Adv Exp Med Biol. 2019. PMID: 31628657 Review.
-
Gasdermin E permits interleukin-1 beta release in distinct sublytic and pyroptotic phases.Cell Rep. 2021 Apr 13;35(2):108998. doi: 10.1016/j.celrep.2021.108998. Cell Rep. 2021. PMID: 33852854 Free PMC article.
-
Seneca Valley virus circumvents Gasdermin A-mediated inflammation by targeting the pore-formation domain for cleavage.mBio. 2024 Oct 16;15(10):e0168024. doi: 10.1128/mbio.01680-24. Epub 2024 Aug 29. mBio. 2024. PMID: 39207099 Free PMC article.
Cited by
-
Identification of the Pyroptosis-Related Gene Signature and Risk Score Model for Colon Adenocarcinoma.Front Genet. 2021 Dec 6;12:771847. doi: 10.3389/fgene.2021.771847. eCollection 2021. Front Genet. 2021. PMID: 34938319 Free PMC article.
-
Pyroptosis and inflammasomes in cancer and inflammation.MedComm (2020). 2023 Sep 24;4(5):e374. doi: 10.1002/mco2.374. eCollection 2023 Oct. MedComm (2020). 2023. PMID: 37752941 Free PMC article. Review.
-
Potential Impact of Climate Change-Induced Alterations on Pyroptotic Cell Death in Animal Cells: A Review.Mol Biotechnol. 2025 May;67(5):1784-1799. doi: 10.1007/s12033-024-01182-x. Epub 2024 May 15. Mol Biotechnol. 2025. PMID: 38748072 Review.
-
Current insights into the regulation of programmed cell death by TP53 mutation in cancer.Front Oncol. 2022 Oct 13;12:1023427. doi: 10.3389/fonc.2022.1023427. eCollection 2022. Front Oncol. 2022. PMID: 36313700 Free PMC article. Review.
-
The role of pyroptosis-related lncRNA risk signature in ovarian cancer prognosis and immune system.Discov Oncol. 2023 Aug 19;14(1):149. doi: 10.1007/s12672-023-00767-3. Discov Oncol. 2023. PMID: 37597098 Free PMC article.
References
-
- Ferlay, J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray. 2015 Mar 1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136 (5): E359–E386. https://doi.org/10.1002/ijc.29210 . - DOI - PubMed
-
- Berkel, C., and E. Cacan. 2021. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer. Hum Cell. 34: 862–877. https://doi.org/10.1007/s13577-021-00486-3 . - DOI - PubMed
-
- Bristow, R.E., R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz. 2002 Mar 1. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 20 (5): 1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248 . - DOI - PubMed
-
- Kyrgiou, M., G. Salanti, N. Pavlidis, E. Paraskevaidis, and J.P. Ioannidis. 2006. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 98 (22): 1655–1663. https://doi.org/10.1093/jnci/djj443 . - DOI - PubMed
-
- Coukos, G., J. Tanyi, and L.E. Kandalaft. 2016. Opportunities in immunotherapy of ovarian cancer. Ann Oncol (Suppl 1): i11–i15. https://doi.org/10.1093/annonc/mdw084 PMID: 27141063; PMCID: PMC4852275.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical